A5015446545- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- COVID-19 Clinical Research Studies
- Acute Myocardial Infarction Research
- Pancreatic function and diabetes
- Long-Term Effects of COVID-19
- Cardiac, Anesthesia and Surgical Outcomes
- Coronary Interventions and Diagnostics
- Cardiac pacing and defibrillation studies
- Intensive Care Unit Cognitive Disorders
- Cardiac Structural Anomalies and Repair
- Pharmaceutical Practices and Patient Outcomes
- Pancreatitis Pathology and Treatment
- Apelin-related biomedical research
- Diabetes and associated disorders
- Pharmacology and Obesity Treatment
- Psychology Research and Bibliometrics
- Developmental and Educational Neuropsychology
- Cardiac Arrhythmias and Treatments
- Inflammasome and immune disorders
Centro de Investigación Biomédica en Red
2017-2025
Centro de Investigación en Red en Enfermedades Cardiovasculares
2017-2025
Complejo Hospitalario Universitario de Santiago
2016-2025
Complexo Hospitalario Universitario A Coruña
2021-2025
Instituto de Salud Carlos III
2023-2025
Instituto de Investigación Sanitaria de Santiago
2022-2024
Universidade de Santiago de Compostela
2022-2024
Hospital Universitario Virgen de la Arrixaca
2024
Universidad de Murcia
2024
Servicio Gallego de Salud
2023
Abstract Background and Aims Acute heart failure (AHF) promotes inflammatory activation, which is associated with worse outcomes. Colchicine has proven effective in other cardiovascular conditions characterized by but never been evaluated the setting of AHF. Methods This multicenter, randomized, double-blind placebo-controlled trial included patients AHF, requiring ≥40 mg intravenous furosemide, regardless their left ventricular ejection fraction (LVEF) inpatient or outpatient setting....
Previous evidence supports that monoclonal antibodies inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 50%-65%, regardless of baseline treatments. We tested possible sex differences in a multicentre registry real-world patients treated with PCSK9 inhibitors.This is and retrospective study 652 initiating treatment any inhibitor 18 different hospitals. Before-treatment on-treatment LDLc medical treatments, clinical...
Abstract Background and Aims Meteorin‐like protein (Metrnl) has been recently suggested as a new adipokine with protective cardiovascular effects. Its circulating levels in patients seem to be associated heart failure (HF), although contradictory results. Our aim was ascertain whether this could estimate the prognosis of HF de novo (DNHF) patients. Methods Metrnl plasma 400 hospitalized DNHF (55% reduced ejection fraction, 17.3% mid‐range 27.8% preserved fraction) were measured by...
The pharmacological inhibition of sodium-glucose cotransporter 2 (SGLT2) has emerged as a treatment for patients with type diabetes mellitus (T2DM), cardiovascular disease and/or other metabolic disturbances, although some the mechanisms implicated in their beneficial effects are unknown. SGLT2 inhibitor (SGLT2i) empagliflozin been suggested regulator adiposity, energy metabolism, and systemic inflammation adipose tissue. aim our study was to evaluate impact 6-week-empagliflozin on lipidome...
Recombinant human relaxin-2 (serelaxin) has been widely proven as a novel drug with myriad effects at different cardiovascular levels, which support its potential therapeutic efficacy in several diseases (CVD). Considering these effects, together the influence of on adipocyte physiology and adipokine secretion, connection between visceral adipose tissue (VAT) dysfunction development CVD, we could hypothesize that may regulate VAT metabolism. Our objective was to evaluate impact 2-week...
IntroductionObesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in efficacy HbA1c; 2) to evaluate safety adherence during titration phase.MethodsIt is a multicenter, prospective, observational study on GLP1 RA naïve patients. The primary end point was %). Changes weight, BMI HbA1c were also calculated...
The primary objective of this study was to conduct a cost-utility analysis proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective conducted across 12 Spanish hospitals from May 2020 April 2022, involving 158 patients hypercholesterolemia or atherosclerotic This assessed health-related quality life (QoL) using the EQ-5D-3L questionnaire. evaluated economic impact...
Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, effect other lipid parameters, such as remnants or, so-called residual risk, is unknown.Multicenter and retrospective registry patients treated with PCSK9 inhibitors from 14 different hospitals in Spain. Before on-treatment parameters were recorded. Residual risk was estimated (1) remnants, (2)...
The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet real-world observational studies. We assessed the function patients initiating PCSK9i, and differences domains, to analyze subgroups by low-density lipoprotein cholesterol (LDL-C) achieved, between alirocumab evolocumab.This a multicenter, quasi-experimental design carried out 12 Spanish hospitals from May 2020 February 2023....
Dapagliflozin has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19) by reducing cytokine production and inflammation. However, there are limited data on its effectiveness. We aimed to evaluate the impact of dapagliflozin COVID-19 severity (including hospitalization risk, ICU admission, in-hospital death progression severe COVID-19) susceptibility infection.We conducted population-based case-control study. For aim 1, we assessed in cases (positive PCR patients...
Abstract Background Most serious complications of infective endocarditis (IE) appear in the so-called “critical phase” disease, which represents first days after diagnosis. The majority patients overcoming acute phase has a favorable outcome, yet they remain hospitalized for long period time mainly to complete antibiotic therapy. major hypothesis this trial is that with clinically stable IE and adequate response treatment, without signs persistent infection, periannular or metastatic foci,...
Abstract: Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid a novel oral drug in therapeutic armamentarium which able to reduce LDLc. The objectives this study were (1) select potential patients for administering bempedoic such as those with very high cardiovascular risk LDLc not achieved despite conventional PCSK9 inhibitors (PCSK9i) and/or statins ezetimibe (2) estimate cost-effectiveness different scenarios....